| | "Break the chain": Review of administrative and health systems response to the COVID-19 pandemic by India's tropical state of Kerala | E-poster | E51 |
| LBPEA01 | Long-acting starch nanoparticle drug delivery system to treat chronic HIV | E-poster | A22 |
| LBPEA02 | Drug resistance to novel non-nucleoside reverse transcriptase inhibitor Elsulfavirine among drug naïve HIV-infected Caucasian and Asian patients | E-poster | A3 |
| LBPEA03 | Vpu inhibitor BIT225 alters T cell activation and homing plasma membrane receptor expression on CD4+T cells (CD28 and CCR7) and monocyte-derived macrophages (CD80 and CD86) | E-poster | A22 |
| LBPEA04 | Novel Gag and Envelope detection assay reveals viral and cellular dynamics during early treatment periods at the single-cell level | E-poster | A16 |
| LBPEA05 | Characterising the serum metabolic profile of HIV/TB co-infection | E-poster | A30 |
| LBPEA06 | Reanalysis of native RNA sequencing of HIV-1 supports spliced HIV mRNA packaging into virions as a new hybrid segmented retrovirus model | E-poster | A2 |
| LBPEB07 | A randomized prospective study evaluating virologic outcomes among patients switching with detectable and undetectable viral loads from efavirenz and nevirapine-based first line ART regimens to DTG regimens in Zambia | E-poster | B32 |
| LBPEB08 | Half of children living with HIV with virologic failure have drug resistance requiring antiretroviral regimen change: early insights from a randomized trial in western Kenya | E-poster | B51 |
| LBPEB09 | Comparative outcomes in hospital admissions with COVID-19 in people living with HIV and people living without HIV: A retrospective study | E-poster | B69 |